PatientsVille.com Logo

HYPOGLYCAEMIA and Mirtazapine

PatientsVille

HYPOGLYCAEMIA Symptoms and Causes

Hypoglycemia means low blood glucose, or blood sugar. Your body needs glucose to have enough energy. After you eat, your blood absorbs glucose. If you eat more sugar than your body needs, your muscles, and liver store the extra. When your blood sugar begins to fall, a hormone tells your liver to release glucose.

In most people, this raises blood sugar. If it doesn't, you have hypoglycemia, and your blood sugar can be dangerously low. Signs include

  • Hunger
  • Shakiness
  • Dizziness
  • Confusion
  • Difficulty speaking
  • Feeling anxious or weak

In people with diabetes, hypoglycemia is often a side effect of diabetes medicines. Eating or drinking something with carbohydrates can help. If it happens often, your health care provider may need to change your treatment plan.

You can also have low blood sugar without having diabetes. Causes include certain medicines or diseases, hormone or enzyme deficiencies, and tumors. Laboratory tests can help find the cause. The kind of treatment depends on why you have low blood sugar.

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Check out the latest treatments for HYPOGLYCAEMIA

HYPOGLYCAEMIA treatment research studies

Mirtazapine clinical trials, surveys and public health registries


Find Drug Side Effect reports



Mirtazapine Side Effects

Completed Suicide (237)
Confusional State (206)
Hyponatraemia (180)
Depression (160)
Overdose (148)
Anxiety (147)
Fall (136)
Dizziness (130)
Agitation (130)
Condition Aggravated (123)
Somnolence (117)
Insomnia (113)
Headache (110)
Serotonin Syndrome (109)
Suicidal Ideation (107)
Fatigue (105)
Loss Of Consciousness (104)
Convulsion (103)
Aggression (103)
Suicide Attempt (100)
Nausea (96)
Oedema Peripheral (93)
Dyspnoea (92)
Weight Increased (90)
Tachycardia (90)
Tremor (84)
Malaise (82)
Vomiting (75)
Restless Legs Syndrome (75)
Myalgia (73)
Alanine Aminotransferase Increased (72)
Cardiac Arrest (71)
Inappropriate Antidiuretic Hormone Secretion (71)
Feeling Abnormal (70)
Toxicity To Various Agents (69)
Asthenia (69)
Diarrhoea (67)
Syncope (62)
Hyperhidrosis (61)
Neuroleptic Malignant Syndrome (61)
Pain In Extremity (61)
Electrocardiogram Qt Prolonged (60)
Pyrexia (59)
Aspartate Aminotransferase Increased (58)
Pulmonary Embolism (57)
Arthralgia (56)
Hypotension (56)
Irritability (56)
Pain (55)
Gait Disturbance (54)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

i have been on citalopram and amatripolineand fluxaitne i have been on 15mg of mirtazapine and tryed 30mg the doc has put me on 45mg and i asked if these tablets dont work what is next hes said shrink as i have tryed all the ones he said but i have

My symptoms were tired, weak, unable to sleep. Was prescribed half of a 15 MG Mirtazapine nightly to help me sleep. Has this drug been successful used as a sleeping aid?

The above comment is too stupid, I actually LOLed at you Pete... lol you gave it 2 days and your complaining about the side-effects? and on 15 mgs? LMAO!!! It takes couple weeks at least to cope with the side-effects; just like m

48 year old male, I have suffered depression all my life. Have used SSRI's for the last ten years with good but mixed results. Last year lost my job due to an episode where I ended up throwing my monitor across the office and have not been able to wo

After a nasty experience with citalapram i was advised by my doc to try mirtazapine and it has suitedme very well. only side effect i canreport is an appetite increase. However as i don't carry much weight that isnt a problem.&

Back pain

Been on 90mg mirtazapine for 6 years twice the recomended dose is this considered safe

Body covered in hives

Does mirtazapine have muscles side effects?

Hi, I have been on mittazapine for 10 days, sleepy , tierd all the time and slugish in response to conversation just horrid feel gastly , head ace, The worst went to bed 11pm took the 15mg pill, went to the loo at 3am and collapse

<span style='font-weight: bold;'><a href='http://sideeffects101.com/drug-side-effects/euglucon-hypoglycaemia.htm' rel='nofollow'>hypoglycaemia</a>, little bit of tremor, dosage was just 2.5mg and treated with diovan 80, celebrex 200

HYPOGLYCAEMIA Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Not yet recruiting The Effect of Hypoglycaemia on Brain Lactate Accumulation and Cerebral Blood Flow
Conditions: Type 1 Diabetes Mellitus;   Hypoglycemia Unawareness
Intervention: Other: glucose clamp
Outcome Measure: Brain lactate concentration
2 Recruiting Etiology, Assessment and Treatment of Post-gastric Bypass Severe Hypoglycemia
Conditions: Obesity;   Hypoglycemia;   Surgery
Interventions: Dietary Supplement: Oral Glucose tolerance test (OGGT);   Other: Isoglycemic intravenous glucose infusion (IIGI);   Dietary Supplement: Liquid mixed meal;   Drug: Octreotide;   Drug: Synthetic Exendin 9-39
Outcome Measures: Changes in biomedical markers (eg. blood glucose) in response to a liquid meal.;   Continuous Glucose Monitoring as an indicator of post-gastric bypass hypoglycemia
3 Recruiting Outpatient Reduction of Nocturnal Hypoglycemia by Using Predictive Algorithms and Pump Suspension in Children
Condition: Type 1 Diabetes
Intervention: Device: Pump suspension algorithm
Outcome Measures: Comparison of the time spent in hypoglycemia (<70 mg/dl, 3.9 mmol/L) overnight on intervention nights versus control nights, normalized to an 8-hour period.;   Percentage of sensor glucose values 71 to 180 mg/dL (3.9 to 10.0 mmol/L);   Proportion of nights with a sensor glucose value <=70 mg/dL (<=3.9 mmol/L);   Proportion of nights with sensor glucose value <=50 mg/dL (<=2.8 mmol/L);   For the nights when sensor glucose is <=60 mg/dL (<= 3.3 mmol/L), tabulation will be made as to whether blood glucose measured with study blood glucose meter;   Mean home glucose meter morning glucose;   Morning glucose measured with home glucose meter >=250 mg/dL (>=13.9 mmol/L);   Morning blood ketones >1.0 mmol/L;   Morning urine ketones >=small amount;   Mean sensor glucose overnight;   Percentage of sensor glucose values 71 to 180 mg/dL (3.9 to 10.0 mmol/L) overnight;   Area under the curve for sensor glucose <70 mg/dL (3.9 mmol/L), 60 mg/dL (3.3 mmol/L), and 50 mg/dL (2.8 mmol/L);   Area under the curve sensor glucose >180 mg/dL (10.0 mmol/L) and 240 mg/dl (13.3 mmol/L) overnight;   Percent of nights with a CGM value > 250 mg/dL (13.9 mmol/L);   Morning glucose measured with home glucose meter >250 mg/dL (13.9 mmol/L);   Morning ketones >0.6 mmol/L;   Episodes of Diabetic Ketoacidosis (DKA);   Episodes of severe hypoglycemia;   Change in Hemoglobin A1c;   All reported adverse events;   The pump settings will be analyzed for any changes from the baseline visit
4 Recruiting Naltrexone and Hypoglycemia in Type 1 Diabetes
Conditions: Type 1 Diabetes;   Hypoglycemia Unawareness
Intervention: Drug: Naltrexone
Outcome Measures: Cerebral blood flow;   Rates of hypoglycemia
5 Unknown  Lactate and Hypoglycemia
Condition: Hypoglycemia
Interventions: Drug: Lactate;   Drug: Glucose
Outcome Measures: Area under the curve of the glycemia;   Bispectral index variation;   Maximum change in glycemia;   Changes in growth hormone and cortisol;   Need for glucose infusion for persistent hypoglycemia
6 Not yet recruiting Hypoglycemia (Low Blood Sugar) and the Heart
Conditions: Hypoglycemia;   Type 2 Diabetes
Intervention:
Outcome Measures: blood sugar measurement;   Monitor cardiac function
7 Recruiting Bariatric Surgery and Reactive Hypoglycemia
Conditions: Obesity With Complications;   Morbid Obesity;   Reactive Hypoglycemia;   Bariatric Surgery
Interventions: Procedure: Gastric Bypass;   Procedure: Sleeve Gastrectomy
Outcome Measures: incidence reactive hypoglycemia;   insulin resistance
8 Recruiting Study on Lixisenatide and Counterregulation to Hypoglycemia
Condition: Type 2 Diabetes
Intervention: Drug: Lixisenatide
Outcome Measures: Glucagon response to hypoglycemia;   Cortisol response to hypoglycemia;   Catecholamines
9 Recruiting Post-Gastric Bypass Hypoglycemia
Condition: Hyperinsulinemic Hypoglycemia
Interventions: Other: high carbohydrate test meal;   Other: high carbohydrate test meal after pre-treatment with rapid acting aspart insulin;   Other: high fructose , low glucose test meal with carbohydrate and caloric content similar to the control meal
Outcome Measure: The primary study endpoint will be occurrence or not of plasma glucose < 60 mg/dL during the 4 hours after the test meal (binary endpoint).
10 Recruiting Hypoglycemia and Autonomic Nervous System Function
Condition: Hypoglycemia
Interventions: Drug: Eplerenone;   Drug: Placebo
Outcome Measures: Modified Oxford method assessment of baroreflex function;   Muscle sympathetic nerve activity;   Catecholamine response to lower-body negative pressure
11 Recruiting Pramlintide (Symlin) for the Treatment of Hypoglycemia Following Gastric Bypass Surgery
Conditions: Hypoglycemia;   Evidence of Previous Gastric Surgery
Intervention: Drug: Pramlintide
Outcome Measures: Hypoglycemia;   meal hormonal responses
12 Recruiting Hypoglycemia in Prader-Willi Syndrome
Conditions: Prader Willi Syndrome;   Hypoglycemia
Intervention: Other: Infants with Prader-Willi Syndrome
Outcome Measure: Presence of hypoglycemia
13 Recruiting Effect of Naltrexone on Counterregulatory Mechanisms in Hypoglycemia
Condition: Hypoglycemia
Intervention: Drug: Naltrexone
Outcome Measure: Hormone Levels
14 Recruiting Measurement of Glucose Metabolism in Humans Using Magnetic Resonance at 4 Tesla. Substudy: Hypoglycemia Unawareness
Conditions: Type 1 Diabetes;   Hypoglycemia Unawareness
Intervention: Drug: somatostatin
Outcome Measure: Brain glucose concentration as measured by NMR spectroscopy
15 Recruiting Hypoglycemia at Initiation of Pump Therapy in Children With Type 1 Diabetes
Condition: Type 1 Diabetes
Intervention: Other: Observation of hypoglycemias frequency 3 days before and after pump initiation
Outcome Measures: Frequency of hypoglycemias;   Frequency of hyperglycemias
16 Unknown  Safety and Efficacy of a Novel Glucagon Formulation in Type 1 Diabetic Patients Following Insulin-induced Hypoglycemia
Condition: Hypoglycemia
Interventions: Drug: glucagon;   Drug: low dose experimental formulation;   Drug: high dose experimental formulation;   Drug: Medium dose experimental glucagon formulation
Outcome Measures: Percentage of responders;   Number of subjects with adverse events;   Area under the serum concentration versus time curve (AUC) of glucagon;   Peak serum concentration (Cmax)of glucagon;   Peak plasma concentration (Cmax) of glucose;   Area under the plasma concentration versus time curve (AUC) of glucose
17 Recruiting Hypoglycemia Associated Autonomic Failure in Type 1 Diabetes Mellitus
Condition: Type 1 Diabetes
Interventions: Drug: Dehydroepiandrosterone;   Drug: Placebo
Outcome Measure: Change in level of catecholamines in blood from baseline
18 Recruiting Evaluation of the Effect of Hypoglycemia With PET and a Norepinephrine Transporter Ligand
Condition: Hypoglycemia
Intervention: Other: Norepinephrine Transporter (NET) ligand
Outcome Measures: norepinephrine transporter (NET) ligand concentrations at Baseline;   norepinephrine transporter (NET) ligand concentrations in hyperinsulinemic-hypoglycemic Condition
19 Recruiting The Effects of RT-CGM on Glycemia and QoL in Patients With T1DM and IHA
Conditions: Type 1 Diabetes Mellitus;   Impaired Hypoglycemia Awareness;   Hypoglycemia Unawareness
Intervention: Device: Real-time continuous glucose monitor
Outcome Measures: Time spent in the euglycemic range;   Quality of life;   Glycemia variables;   Hypoglycemic episodes;   Changes in hypoglycemia awareness score
20 Unknown  Do Sulphonylureas Preserve Cortical Function During Hypoglycaemia?
Condition: Type 1 Diabetes Mellitus
Intervention: Drug: Glibenclamide
Outcome Measures: Glucose threshold for development of symptoms and cognitive impairment due to Hypoglycaemia;   Improvement in counter regulatory hormone response to Hypoglycaemia